Hemostasis Today

May, 2026
May 2026
M T W T F S S
 123
45678910
11121314151617
18192021222324
25262728293031
W. Alberto Sifuentes Giraldo: An Overview of Thrombotic Risk and Diagnostic Criteria in Antiphospholipid Syndrome
May 3, 2026, 05:08

W. Alberto Sifuentes Giraldo: An Overview of Thrombotic Risk and Diagnostic Criteria in Antiphospholipid Syndrome

W. Alberto Sifuentes Giraldo, Rheumatologist at Hospital Nuestra Señora de Sonsoles (Sacyl), shared a post on X:

Antiphospholipid Syndrome

Rare systemic autoimmune disease (prevalence: 50 per 100,000 in females and 9.8 per 100,000 in males) responsible for thrombotic events and obstetric morbidity in individuals with persistent antiphospholipid autoantibodies:

  • anticardiolipin antibodies IgG or IgM
  • anti-β2-glycoprotein-I antibodies IgG or IgM
  • lupus anticoagulants

It is a leading cause of acquired thrombophilia, accounting for 10 percent of arterial or venous thrombosis.

These thrombotic events can lead to acute organ dysfunction or failure, sometimes requiring intensive care unit admission, or can even escalate into a ‘thrombotic storm’ called the catastrophic antiphospholipid syndrome.

Classification criteria for antiphospholipid syndrome have very been updated in 2023 by the American College of Rheumatology (ACR) and the European League Against Rheumatism (EULAR).

These criteria are applicable to patients with at least one positive laboratory test within 3 years of a clinical manifestation.

Clinical manifestation of antiphospholipid syndrome.”

W. Alberto Sifuentes Giraldo: An Overview of Thrombotic Risk and Diagnostic Criteria in Antiphospholipid Syndrome

Stay updated with Hemostasis Today.